ICU Medical (ICUI) UBS Global Healthcare Conference 2024 summary

Business overview and portfolio

• Focuses on infusion therapy, breaking business into consumables, infusion pumps, and vital care segments.

• Consumables include needle-free connectors and vascular access, with a $1B franchise compounding at 6% annually.

• Infusion pumps cover all modalities, with recent innovation in the Plum Duo and upcoming Solo and next-gen pumps.

• Vital care includes IV solutions, respiratory, and temperature management products.

• 75% of sales are single-use disposables, with 70% of revenue from North America.

Recent strategic actions and financials

• Announced a joint venture with Otsuka to expand IV solutions capacity and reduce single-site risk.

• Transaction brings $200M after-tax cash, deconsolidates $350M revenue, and improves gross margins by 300-400 bps.

• Net debt expected to fall to ~$1B by end of 2025, with leverage targeted at 2x-2.5x by 2026.

• Margin improvement initiatives include plant closures, logistics, and service optimization.

• Free cash flow and contract renewals have improved, supporting a shift from debt to equity value.

Market dynamics and growth drivers

• Infusion market is highly consolidated with high regulatory barriers and sticky customer relationships.

• Software and connectivity are key innovation areas, with LifeShield platform central to future differentiation.

• Growth in consumables driven by brand, innovation, and economic bundling; Smiths Medical acquisition stabilized and now contributing.

• Mandates for device repair by end of 2026 expected to drive pump upgrades and share gains over 2-3 years.

• ASC strategy leverages direct and distributor sales, offering turnkey solutions for alternate sites of care.